Document ID: chunk:federal_register_of_legislation:F2013C00288:reg:3:p8
Version: federal_register_of_legislation:F2013C00288
Segment Type: reg
Provision Reference: reg 3 (pt 8/9)
Character Range: 2895517–2898551

identified in the endnotes.

Modifications

If a provision of the compiled instrument is affected by a textual modification that is in force, the text of the modifying provision is set out in the endnotes.

Provisions ceasing to have effect

If a provision of the compiled instrument has expired or otherwise ceased to have effect in accordance with a provision of the instrument, details of the provision are set out in the endnotes.

 Page
1 Introduction
1.1 Background
1.2 Purpose of HILs
1.3 Interpretation and use of the HILs
1.3.1 Limitations on the use of the HILs
1.3.2 What does 'exceedence' of an HIL mean?
1.4 Principles and methodology for generating the HILs
1.5 Objectives
2 Presentation of the health-based investigation
levels
2.1 Stockholm Convention
2.2 Summary of HILs
2.2.1 Laboratory level of reporting
2.2.2 Polycyclic aromatic hydrocarbons
2.2.3 Toxicity surrogate approach
2.2.4 Inorganic mercury
2.2.5 PCBs
2.2.6 Interim HILs for volatile organic chlorinated
compounds
2.2.7 Free cyanide
2.2.8 Home-grown produce
3 Generic land use scenarios
3.1 Introduction
3.2 Description of the generic land use scenarios
3.2.1 HIL A values – residential land use scenario with
garden/accessible soil
3.2.2 HIL B values  residential scenario with minimal
opportunities for soil access
3.2.3 HIL C values  public open space scenario
3.2.4 HIL D values - commercial/ industrial scenario
3.2.5 Sensitive populations
3.3 Exposure pathways
3.4 Application of the HILs to alternative land use scenarios
4 Toxicity assessment
4.1 Sources of toxicity data
4.2 Approach for carcinogenic contaminants
4.3 Toxicity approach for dermal exposure
4.4 Background exposure and contribution of soil to total
exposure
4.5 Bioavailability and bioaccessibility
4.6 Speciation
4.7 Toxicity of groups of substances
5 Exposure assessment
5.1 Exposure pathways
5.2 General human characteristics applied in the derivation
of the HILs
5.2.1 Body weight
5.2.2 Exposure duration and frequency
5.2.3 Averaging time
5.3 Pathway-specific exposure assumptions
5.3.1 Incidental ingestion of surface soil and dust
5.3.2 Dermal contact with surface soil and dust particulates
5.3.3 Indoor and outdoor inhalation of dust
5.3.4 Indoor and outdoor inhalation of vapours derived
from soil
5.3.5 Consumption of home-grown produce
5.4 Blood lead modelling
5.4.1 Modelling adult exposures to lead
5.4.2 Modelling child exposures to lead
5.4.3 Bioavailability and bioaccessibility of lead
5.5 Vapour assessment
5.5.1 Introduction
5.5.2 Indoor exposures
5.5.3 Outdoor exposures
6 Risk characterisation  how the HILs were
generated
6.1 Risk characterisation and calculation of HILs
6.2 Target risk levels
6.3 Presentation of HILs
6.4 Uncertainty and sensitivity analysis
6.4.1 HIL uncertainty analysis
6.5 HIL sensitivity analysis
6.5.1 Soil fraction of organic carbon
6.5.2 Vapour intrusion rate
7 Bibliography
8 Glossary
9 Shortened forms
Appendix A Derivation of HILs and interim HILs
Appendix B Equations for derivation of HILs and interim HILs